

Christopher T Ritchlin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3641723/christopher-t-ritchlin-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

202
papers

11,563
citations

53
h-index

105
g-index

243
ext. papers

13,917
ext. citations

6.7
avg, IF

6.5
L-index

#	Paper	IF	Citations
202	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3279-89		712
201	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 957-970	59.2	586
200	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015 , 386, 1137-46	40	566
199	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet, The</i> , 2013 , 382, 780-9	40	557
198	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1060-71	9.5	485
197	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 990-9	2.4	465
196	Mechanisms of TNF- α and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. <i>Journal of Clinical Investigation</i> , 2003 , 111, 821-831	15.9	393
195	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 79-87	2.4	341
194	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
193	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 6-16	2.4	308
192	Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. <i>New England Journal of Medicine</i> , 2014 , 370, 2295-306	59.2	298
191	Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. <i>Arthritis and Rheumatism</i> , 2007 , 56, 476-88		231
190	Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , 2011 , 63, 939-48		218
189	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1000-6	2.4	211
188	Mechanisms of TNF- α - and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. <i>Journal of Clinical Investigation</i> , 2003 , 111, 821-31	15.9	187
187	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. <i>American Journal of Human Genetics</i> , 2015 , 97, 816-36	11	185
186	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 5-32	9.5	178

185	Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. <i>Arthritis and Rheumatism</i> , 2004 , 50, 265-76		176
184	Assessment of patients with psoriatic arthritis: a review of currently available measures. <i>Arthritis and Rheumatism</i> , 2004 , 50, 24-35		151
183	Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. <i>Arthritis Research</i> , 2000 , 2, 356-60		138
182	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019 , 71, 2-29	4.7	137
181	Consensus guidelines for the management of plaque psoriasis. <i>Archives of Dermatology</i> , 2012 , 148, 95-102		135
180	Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2666-76		127
179	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 153-166	8.1	111
178	Clinical development of anti-RANKL therapy. <i>Arthritis Research and Therapy</i> , 2007 , 9 Suppl 1, S7	5.7	107
177	National Psoriasis Foundation clinical consensus on disease severity. <i>Archives of Dermatology</i> , 2007 , 143, 239-42		106
176	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1984-1988	2.4	101
175	Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. <i>Molecular Medicine</i> , 2005 , 11, 21-9	6.2	101
174	Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2010 , 62, 917-28		96
173	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1112-1124	9.5	94
172	Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1115-1125	4.0	93
171	Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2017 , 56, 1993-2003	3.9	92
170	Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>Rheumatology and Therapy</i> , 2016 , 3, 91-102	4.4	92
169	Metabolic disorders in patients with psoriasis and psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2006 , 8, 355-63	4.9	91
168	From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 94-105	4.5	87

167	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020 , 395, 1496-1505	4.0	83
166	Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. <i>Journal of Rheumatology</i> , 2006 , 33, 1417-21	4.1	82
165	CD16 (FcRgammalll) as a potential marker of osteoclast precursors in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R14	5.7	81
164	RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens. <i>Journal of Cellular Physiology</i> , 2010 , 223, 76-83	7	72
163	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015 , 67, 1739-49	4.7	71
162	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018 , 20, 47	5.7	69
161	Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. <i>Arthritis and Rheumatism</i> , 2007 , 56, 4024-37		68
160	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020 , 395, 427-440	4.0	65
159	Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 79-92	6.3	64
158	Psoriatic disease--from skin to bone. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 698-706		64
157	Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Arthritis Care and Research</i> , 2017 , 69, 1692-1699	4.7	62
156	Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 94-106	8.1	62
155	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 2095-6	59.2	60
154	DC-STAMP: A Key Regulator in Osteoclast Differentiation. <i>Journal of Cellular Physiology</i> , 2016 , 231, 2402-7		59
153	Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. <i>Arthritis Research and Therapy</i> , 2010 , 12, R113	5.7	59
152	Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1469-1480	6.3	58
151	Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. <i>Arthritis Research and Therapy</i> , 2011 , 13, R209	5.7	58
150	The diagnosis and treatment of early psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 634-41	8.1	54

149	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 743-750	8.1	52
148	New therapies for psoriasis and psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 204-10	5.3	52
147	Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2018 , 45, 1389-1396	4.1	51
146	In vivo quantification of lymph viscosity and pressure in lymphatic vessels and draining lymph nodes of arthritic joints in mice. <i>Journal of Physiology</i> , 2014 , 592, 1213-23	3.9	49
145	MRI and quantification of draining lymph node function in inflammatory arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1117, 106-23	6.5	49
144	Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. <i>Journal of Rheumatology</i> , 2015 , 42, 1439-42	4.1	45
143	Etiology and Pathogenesis of Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 643-63	2.4	45
142	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1254-1268	4.5	42
141	Pathogenesis of psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 406-12	5.3	41
140	Collagenase in synovitis of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1992 , 22, 44-53	5.3	41
139	Pathogenesis of psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 338-43	5.3	40
138	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. <i>Rheumatology</i> , 2019 , 58, 197-205	3.9	40
137	Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow. <i>Arthritis and Rheumatism</i> , 2013 , 65, 130-8		39
136	Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 119-128	5.4	39
135	Differential expression of the small inducible cytokines GRO alpha and GRO beta by synovial fibroblasts in chronic arthritis: possible role in growth regulation. <i>Cytokine</i> , 1994 , 6, 61-9	4	37
134	MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E7917-E7926	11.5	36
133	Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2290-4	4.1	36
132	Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2019-29		36

131	Quantitative electroencephalography. A new approach to the diagnosis of cerebral dysfunction in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1992 , 35, 1330-42		36
130	Targeting the interleukin-23/17 axis in axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 359-67	5.3	36
129	CD23(+)/CD21(hi) B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice. <i>Arthritis Research and Therapy</i> , 2011 , 13, R138	5.7	34
128	Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA. <i>Journal of Rheumatology</i> , 2014 , 41, 2273-6	4.1	33
127	The role of the lymphatic system in inflammatory-erosive arthritis. <i>Seminars in Cell and Developmental Biology</i> , 2015 , 38, 90-7	7.5	31
126	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
125	Patients with rheumatoid arthritis in clinical remission manifest persistent joint inflammation on histology and imaging studies. <i>Journal of Rheumatology</i> , 2014 , 41, 2153-60	4.1	29
124	Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1127-37		29
123	Autoimmunity and bone. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1068, 275-83	6.5	29
122	Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 111-7	5.3	27
121	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. <i>Journal of Rheumatology</i> , 2018 , 45, 378-384	4.1	27
120	Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. <i>Journal of Rheumatology</i> , 2010 , 37, 2566-72	4.1	27
119	An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform. <i>Journal of Immunological Methods</i> , 2009 , 341, 106-16	2.5	27
118	Altered bone biology in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2012 , 14, 349-57	4.9	24
117	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 1107-1123	2.1	24
116	Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 515-26	5.4	23
115	Altered bone remodeling in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2008 , 10, 311-7	4.9	23
114	Treatment update on spondyloarthropathy. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 247-56	5.3	23

113	Therapies for psoriatic enthesopathy. A systematic review. <i>Journal of Rheumatology</i> , 2006 , 33, 1435-8	4.1	23
112	From skin to bone: translational perspectives on psoriatic disease. <i>Journal of Rheumatology</i> , 2008 , 35, 1434-7	4.1	22
111	Composite measures in psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 453-61	4.1	21
110	Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions. <i>Calcified Tissue International</i> , 2018 , 102, 559-574	3.9	20
109	GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1237-9	4.1	20
108	Brief Report: Treatment of Tumor Necrosis Factor-Transgenic Mice With Anti-Tumor Necrosis Factor Restores Lymphatic Contractions, Repairs Lymphatic Vessels, and May Increase Monocyte/Macrophage Egress. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1187-1193	9.5	19
107	Lymphatic imaging to assess rheumatoid flare: mechanistic insights and biomarker potential. <i>Arthritis Research and Therapy</i> , 2016 , 18, 194	5.7	19
106	Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1812-1822	4.7	19
105	Bone remodeling in psoriasis and psoriatic arthritis: an update. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 66-75	5.3	18
104	Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis. <i>Arthritis Care and Research</i> , 2015 , 67, 829-35	4.7	17
103	Thy1 is a positive regulator of osteoblast differentiation and modulates bone homeostasis in obese mice. <i>FASEB Journal</i> , 2018 , 32, 3174-3183	0.9	16
102	Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca ²⁺ /NFATc1 Axis. <i>Journal of Cellular Physiology</i> , 2017 , 232, 2538-2549	7	16
101	Axial spondyloarthritis: new advances in diagnosis and management. <i>BMJ, The</i> , 2021 , 372, m4447	5.9	15
100	Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies. <i>Journal of Rheumatology</i> , 2016 , 43, 1637-42	4.1	14
99	Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 448-52	4.1	14
98	Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology. <i>Current Rheumatology Reviews</i> , 2019 , 15, 277-289	1.6	14
97	Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. <i>BMC Rheumatology</i> , 2019 , 3, 52	2.9	14
96	Selective Sexual Dimorphisms in Musculoskeletal and Cardiopulmonary Pathologic Manifestations and Mortality Incidence in the Tumor Necrosis Factor-Transgenic Mouse Model of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1512-1523	9.5	13

95	Mechanistic insights from animal models of psoriasis and psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2013 , 15, 377	4.9	13
94	Recent advances in the treatment of the seronegative spondyloarthropathies. <i>Current Rheumatology Reports</i> , 2001 , 3, 399-403	4.9	13
93	Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy. <i>PLoS ONE</i> , 2014 , 9, e110657	3.7	13
92	Strategies to Improve Outcomes in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2019 , 21, 72	4.9	13
91	Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2017 , 44, 1151-1158	4.1	11
90	Troponin T3 expression in skeletal and smooth muscle is required for growth and postnatal survival: characterization of Tnnt3(tm2a(KOMP)Wtsi) mice. <i>Genesis</i> , 2013 , 51, 667-75	1.9	11
89	Chronic social stress Ameliorates psoriasiform dermatitis through upregulation of the Hypothalamic-Pituitary-Adrenal axis. <i>Brain, Behavior, and Immunity</i> , 2018 , 68, 238-247	16.6	11
88	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naïve Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 1458-1461	4.1	10
87	Psoriasis: Psychosomatic, somatopsychic, or both?. <i>Clinics in Dermatology</i> , 2018 , 36, 698-703	3	10
86	Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 462-7	4.1	10
85	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. <i>Rheumatology</i> , 2021 , 60, 2109-2121	3.9	10
84	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNF-inhibitor-experienced. <i>RMD Open</i> , 2021 , 7,	5.9	10
83	Validation of power Doppler versus contrast-enhanced magnetic resonance imaging quantification of joint inflammation in murine inflammatory arthritis. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 690-4	6.3	9
82	Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. <i>Journal of Rheumatology</i> , 2011 , 38, 2572-80	4.1	9
81	Biomarkers of radiographic progression in psoriatic arthritis: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , 2012 , 39, 2189-92	4.1	9
80	High-resolution uniform MR imaging of finger joints using a dedicated RF coil at 3T. <i>Journal of Magnetic Resonance Imaging</i> , 2010 , 31, 240-7	5.6	9
79	iNOS dependent and independent phases of lymph node expansion in mice with TNF-induced inflammatory-erosive arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 240	5.7	9
78	Measuring intranodal pressure and lymph viscosity to elucidate mechanisms of arthritic flare and therapeutic outcomes. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1240, 47-52	6.5	8

77	Newer therapeutic approaches: spondyloarthritis and uveitis. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 75-90, viii	2.4	8
76	Altered Lymphatic Vessel Anatomy and Markedly Diminished Lymph Clearance in Affected Hands of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1447-1455	9.5	7
75	GRAPPA Trainees Symposium 2013: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1200-5	4.1	7
74	Translational perspectives on psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , 2009 , 83, 30-4		7
73	Etanercept in psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2003 , 3, 169-77	5.4	7
72	Opportunities and challenges in the treatment of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 440-452	5.3	7
71	The role of bone marrow edema and lymphangiogenesis in inflammatory-erosive arthritis. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 658, 1-10	3.6	7
70	Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1759-1770	9.5	6
69	Relationship Between Lymph Node Volume and Pain Following Certolizumab Therapy for Rheumatoid Arthritis Flare: A Pilot Study. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016 , 9, 203-208	2.3	6
68	Psoriatic enthesitis: an update from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1220-3	4.1	6
67	GRAPPA Trainees Symposium 2009: a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , 2011 , 38, 526-9	4.1	6
66	Biomarker development in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012 , 89, 57-60		6
65	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019 , 95, 54-57	4.1	6
64	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020 , 96, 53-57	4.1	6
63	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020 , 22, 78	4.9	6
62	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 31-58	1.1	6
61	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	6
60	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 238-243	8.1	6

59	The joint in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S20-5	2.2	6
58	Go with the flow-hidden vascular passages in bone. <i>Nature Metabolism</i> , 2019 , 1, 173-174	14.6	5
57	Measuring outcomes in ankylosing spondylitis: pearls and pitfalls. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 109-117	5.3	5
56	GRAPPA Trainees Symposium 2011: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , 2012 , 39, 2184-8	4.1	5
55	Biomarkers to Diagnose Early Arthritis in Patients With Psoriasis. <i>Psoriasis Forum</i> , 2012 , 18, 2-10		5
54	TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21/CD23 B Cell Follicles Is Prevented with Anti-TNF Therapy. <i>Journal of Immunology</i> , 2019 , 203, 2837-2849	5.3	5
53	Immunologic advances reveal new targets in psoriasis and psoriatic arthritis. <i>Discovery Medicine</i> , 2015 , 20, 169-75	2.5	5
52	GRAPPA Treatment Recommendations: An Update from the GRAPPA 2014 Annual Meeting and GRAPPA Meeting Adjacent to the 2014 ACR Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1052-1055	4.1	4
51	Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>RMD Open</i> , 2018 , 4, e000638	5.9	4
50	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. <i>Rheumatology</i> , 2021 , 60, 5337-5350	3.9	4
49	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , 2019 , 58, 1025-1033	3.9	4
48	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , 2020 , 72, 1579-1588	4.7	4
47	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 684-685	4.1	3
46	IL12/IL23 Inhibition in the Treatment of Psoriatic Arthritis. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 197-209	1.3	3
45	New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. <i>Clinical Rheumatology</i> , 2020 , 39, 1829-1838	3.9	3
44	A critical role for the protein kinase PKK in the maintenance of recirculating mature B cells and the development of B1 cells. <i>Immunology Letters</i> , 2016 , 172, 67-78	4.1	3
43	GRAPPA Trainees Symposium 2014: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1016-1020	4.1	3
42	Spondyloarthritis: Closing the gap in psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 704-5	8.1	3

41	High-resolution interleaved water-fat MR imaging of finger joints with chemical-shift elimination. <i>Journal of Magnetic Resonance Imaging</i> , 2011 , 33, 245-51	5.6	3
40	The efficacy and safety of adalimumab in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2006 , 8, 329-329	4.9	3
39	The efficacy and safety of alefacept in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2006 , 8, 330-331	4.9	3
38	Efficacy and safety of infliximab for the treatment of psoriatic arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 300-1		3
37	Receptor activator of nuclear ??B ligand and osteoprotegerin: where are we now and what about future treatment uses?. <i>Current Opinion in Orthopaedics</i> , 2005 , 16, 370-375		3
36	Lineage tracing reveals evidence of a popliteal lymphatic muscle progenitor cell that is distinct from skeletal and vascular muscle progenitors. <i>Scientific Reports</i> , 2020 , 10, 18088	4.9	3
35	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1815-1823	4.1	3
34	GRAPPA Trainees Symposium 2015: A Report from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016 , 43, 952-8	4.1	3
33	Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody. <i>Immunological Investigations</i> , 2014 , 43, 606-15	2.9	2
32	MRI outcomes in AS patients after two years of etanercept therapy. <i>Current Rheumatology Reports</i> , 2006 , 8, 253-4	4.9	2
31	Infliximab in psoriatic arthritis. <i>Future Rheumatology</i> , 2007 , 2, 13-22		2
30	Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020 , 96, 19-24	4.1	2
29	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020 , 2, 543-554	3.5	2
28	New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2112-2122.e3	4.3	2
27	Demonstration of Functional Deficiencies in Popliteal Lymphatic Vessels From TNF-Transgenic Mice With Inflammatory Arthritis. <i>Frontiers in Physiology</i> , 2021 , 12, 745096	4.6	2
26	Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 679-683	4.1	1
25	An Integrative Approach to Biomarker Development in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2015 , 93, 43-7		1
24	Summary of the International Federation of Psoriasis Associations (IFPA) meeting: a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , 2011 , 38, 530-9	4.1	1

23	The quest for a biomarker of circulating osteoclast precursors. <i>Arthritis Research and Therapy</i> , 2009 , 11, 113	5.7	1
22	Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha agents. <i>Postgraduate Medicine</i> , 2004 , 116, 31-6, 39-40	3.7	1
21	Collagenase and stromelysin expression in rheumatoid synovium and cartilage: comment on the article by Wolfe et al. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1831-3		1
20	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
19	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	1
18	Pathogenesis of Psoriatic Arthritis 2007 , 48-60		1
17	Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. <i>Pharmacology & Therapeutics</i> , 2021 , 107925	13.9	1
16	Differences in oxylipin profile in psoriasis versus psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 200	5.7	1
15	Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 64	5.7	1
14	GRAPPA Trainees Symposium 2016: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 661-667	4.1	0
13	Navigating the diverse immune landscapes of psoriatic arthritis. <i>Seminars in Immunopathology</i> , 2021 , 43, 279-290	12	0
12	Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints. <i>Rheumatology</i> , 2021 , 60, iv16-iv27	3.9	0
11	Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).. <i>Rheumatology and Therapy</i> , 2022 , 1	4.4	0
10	Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022 , 7, 17-23	1.1	0
9	Disease Modification in Psoriatic Arthritis. <i>Current Treatment Options in Rheumatology</i> , 2018 , 4, 197-213	1.3	
8	Biomarkers to Diagnose Early Arthritis in Patients with Psoriasis. <i>Psoriasis Forum</i> , 2012 , 18a, 48-56		
7	Radiographic progression in ankylosing spondylitis patients treated with infliximab. <i>Current Rheumatology Reports</i> , 2006 , 8, 253-4	4.9	
6	Doxycycline in undifferentiated spondyloarthropathy. <i>Current Rheumatology Reports</i> , 2005 , 7, 171-2; discussion 172	4.9	

- 5 Pseudoxanthoma elasticum masquerading as Sjögren's syndrome. *Journal of Clinical Rheumatology*, **2002**, 8, 89-93 1.1
- 4 Alternative pathways of inflammation in rheumatoid arthritis. *Clinical Immunology Newsletter*, **1996**, 16, 57-62
- 3 Etiology and pathogenesis of psoriatic arthritis **2015**, 998-1007
- 2 Mechanisms of Bone Remodelling in Psoriatic Arthritis **2016**, 111-126
- 1 Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis. *Arthritis and Rheumatology*, **2021**, 73, 1574-1578 9.5